SY-008

SY-008 is an investigational small molecule drug that acts as a sodium-glucose cotransporter 1 (SGLT1) inhibitor. It is being developed primarily for the treatment of type 2 diabetes mellitus. By inhibiting SGLT1, SY-008 aims to reduce glucose absorption in the intestine, thereby lowering blood glucose levels independently of pancreatic beta cell function. This mechanism may offer benefits in both early and advanced stages of diabetes and could potentially improve metabolic state without causing weight gain or hypoglycemia. The drug has been developed by Yabao Pharmaceutical Group and Eli Lilly, with clinical trials conducted in China and Singapore reaching Phase 1 status[1][2][3][4].